MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)
Authors:
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 112, 106769
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathwayJournal of Cancer Research and Clinical Oncology, 2014
- Diffuse large B-cell lymphoma—treatment approaches in the molecular eraNature Reviews Clinical Oncology, 2013
- Diffuse large B-cell lymphomaCritical Reviews in Oncology/Hematology, 2013
- MYC on the Path to CancerCell, 2012
- My Treatment Approach to Patients With Diffuse Large B-Cell LymphomaMayo Clinic Proceedings, 2012
- Relapsed/Refractory Diffuse Large B-Cell LymphomaHematology-American Society Hematology Education Program, 2011
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkersNature Cell Biology, 2008
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- MicroRNAsCell, 2004
- Lasp‐1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domainsFEBS Letters, 1995